Evidence map›Paper›PMID 38586421›Full record

ArticleHeliyon2024

Preclinical characterization of Pan-NKG2D ligand-binding NKG2D receptor decoys.

Peter B Rupert, Matthew Buerger, Emily J Girard, Marie Frutoso, Don Parrilla, Kevin Ng, Theodore Gooley, Veronika Groh, Roland K Strong

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Peter B RupertDivision of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Matthew BuergerDivision of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Emily J GirardClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Marie FrutosoDivision of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Don ParrillaDivision of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Kevin NgDivision of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Theodore GooleyDivision of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Veronika GrohDivision of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Roland K StrongDivision of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NKG2D and its ligands are critical regulators of protective immune responses controlling infections and cancer, defining a crucial immune signaling axis. Current therapeutic efforts targeting this axis almost exclusively aim at enhancing NKG2D-mediated effector functions. However, this axis can drive disease processes when dysregulated, in particular, driving stem-like cancer cell reprogramming and tumorigenesis through receptor/ligand self-stimulation on tumor cells. Despite complexities with its structure and biology, we developed multiple novel engineered proteins that functionally serve as axis-blocking NKG2D "decoys" and report biochemical, structural,

Indexed as

Engineered biologic immunotherapeuticsNatural killer cell receptorsNKG2DX-ray crystallography

Identifiers

PMID38586421
PMCPMC10998067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.